By Fineline Cube 
Aureka Biotechnologies, a pioneer in generative antibody drug development, announced today the successful close of its Series A financing round valued at several million dollars. The round was co‑led by 5Y Capital and Qiming Venture Partners, with continued participation from existing shareholder NRL Capital and additional investors including Agentic Ventures.
Financing Highlights
| Item | Detail |
|---|---|
| Round Size | Multi‑million‑dollar (exact amount undisclosed) |
| Lead Investors | 5Y Capital, Qiming Venture Partners |
| Existing Backers | NRL Capital |
| Other Participants | Agentic Ventures, plus a syndicate of strategic angels |
| Use of Proceeds | • Advance proprietary pipelines to key clinical milestones (PCC & pre‑IND) • Accelerate construction of an integrated wet‑lab/dry‑lab intelligent‑agent platform for antibody design • Expand deep‑tech collaborations with global biopharma partners |
| Closing Date | 10 Nov 2025 |
Company Overview & Technology Platform
- Mission: Build the world’s first data‑driven, closed‑loop generative antibody discovery engine that unites high‑throughput single‑cell functional screening, yeast intracellular automated directed evolution, and a structure‑informed autonomous evolution design agent.
- Platform Architecture:
Wet‑lab (high‑throughput functional assays, yeast evolution) ↔ Dry‑lab (AI‑driven design, structural modeling) → Iterative feedback loop for rapid antibody optimization. - Strategic Partnerships: Active joint projects with leading European and U.S. pharmaceutical companies targeting complex antigens and novel mechanisms, showcasing superior hit‑rates and development speed versus conventional platforms.
Pipeline Progress
| Therapeutic Area | Program Stage | Highlights |
|---|---|---|
| Autoimmune Diseases | Pre‑Candidate Compound (PCC) | Lead antibody shows >80 % target engagement in in‑vitro disease models. |
| Metabolic Diseases | Pre‑IND | IND‑enabling toxicology package on track; expected filing Q2 2026. |
| Additional Targets | Early Discovery | Multiple high‑affinity binders generated via autonomous evolution; candidates entering PCC pipeline. |
- Revenue Track: Over the past 24 months, Aureka generated tens of millions of USD in commercial revenue from platform‑as‑a‑service agreements and early‑stage licensing deals.
- Future Outlook: Management is pursuing mid‑to‑long‑term co‑development and joint‑venture opportunities to expand the pipeline and broaden market reach.
Market Impact & Analyst Perspective
- Capital Infusion: The Series A validates investor confidence in generative AI‑driven biologics, a segment projected to attract $5 bn+ in venture capital by 2027.
- Competitive Edge: Aureka’s integrated wet‑lab/dry‑lab loop offers a speed‑to‑clinic advantage—potentially halving the typical antibody discovery timeline (12–18 months vs. 24–30 months).
- Strategic Fit: Partnerships with established pharma players could accelerate pipeline de‑risking and provide a fast‑track to global market entry for its autoimmune and metabolic candidates.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding financing terms, pipeline timelines, and commercial expectations for Aureka Biotechnologies. Actual results may differ due to risks including regulatory approvals, clinical outcomes, and market adoption.